Lilly directed to pay $176.5m by US court to Teva in migraine drug patent case
In the trial, the jury found that Lilly's migraine drug Emgality infringed three Teva patents and the infringements…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 Nov 22
In the trial, the jury found that Lilly's migraine drug Emgality infringed three Teva patents and the infringements…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Nov 22
Companies are seeing an increasing necessity to work jointly with their partners in supply and manufacturing to ensure…
09 Nov 22
Sanofi will make upfront and target nomination fees totalling up to $21.5m for identifying, synthesising and advancing up…
09 Nov 22
The approval was based on better survival results of Libtayo plus chemotherapy in comparison to chemotherapy alone in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Nov 22
The combined company will leverage VillageMD’s expertise in value-based care and Summit Health-CityMD’s expertise in multispecialty, connected care…
08 Nov 22
Oyster Point owns the FDA-approved Tyrvaya, which is used for the treatment of dry eye disease, while Famy…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
07 Nov 22
Doubling down on innovation and technology, Arab Health will also host the second edition of the Future Health…
07 Nov 22
Beyfortus is a long-acting antibody, indicated for the prevention of lower respiratory tract disease caused by respiratory syncytial…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
07 Nov 22
EMPA-KIDNEY is a randomised, double-blind, placebo-controlled clinical trial that studied the effect of Jardiance (empagliflozin) on progression of…
04 Nov 22
The Breakthrough Therapy Designation was granted based on updated data from the Phase 2 MagnetisMM-3 study, in which…